Ghobrial Irene M, McCormick Daniel J, Kaufmann Scott H, Leontovich Alexey A, Loegering David A, Dai Nga T, Krajnik Kelly L, Stenson Mary J, Melhem Mona F, Novak Anne J, Ansell Stephen M, Witzig Thomas E
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Blood. 2005 May 1;105(9):3722-30. doi: 10.1182/blood-2004-10-3999. Epub 2005 Jan 13.
Mantle-cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable. In order to understand the pathogenesis of MCL and design new therapies, it is important to accurately analyze molecular changes in pathways dysregulated in MCL. We used antibody microarrays to compare patterns of protein expression between CD19(+) purified B lymphocytes from normal tonsil and 7 cases of histologically confirmed MCL. Protein overexpression was defined as a higher than 1.3-fold or 2-fold increase in at least 67% of tumor samples compared with normal B-cell control. Of the polypeptides, 77 were overexpressed using the higher than 1.3-fold cutoff, and 13 were overexpressed using the 2-fold cutoff. These included cell cycle regulators (regulator of chromosome condensation 1 [RCC1], murine double minute 2 [MDM2]), a kinase (citron Rho-interacting kinase [CRIK]), chaperone proteins (heat shock 90-kDa protein [Hsp90], Hsp10), and phosphatase regulators (A-kinase anchor protein 1 [AKAP149], protein phosphatase 5 [PP5], and inhibitor 2). The elevated expression of some of these polypeptides was confirmed by immunoblotting and immunohistochemistry, whereas elevated expression of others could not be confirmed, illustrating the importance of confirmatory studies. This study describes a novel technique that identifies proteins dysregulated in MCL.
套细胞淋巴瘤(MCL)是B细胞非霍奇金淋巴瘤(NHL)的一种独特亚型,侵袭性强且难以治愈。为了了解MCL的发病机制并设计新的治疗方法,准确分析MCL中失调通路的分子变化非常重要。我们使用抗体微阵列比较了来自正常扁桃体的CD19(+)纯化B淋巴细胞与7例组织学确诊的MCL之间的蛋白质表达模式。蛋白质过表达定义为与正常B细胞对照相比,至少67%的肿瘤样本中蛋白质增加超过1.3倍或2倍。在这些多肽中,使用高于1.3倍的临界值有77种过表达,使用2倍临界值有13种过表达。这些包括细胞周期调节因子(染色体凝聚调节因子1 [RCC1]、小鼠双微体2 [MDM2])、一种激酶(西特龙Rho相互作用激酶[CRIK])、伴侣蛋白(热休克90 kDa蛋白[Hsp90]、Hsp10)以及磷酸酶调节因子(A激酶锚定蛋白1 [AKAP149]、蛋白磷酸酶5 [PP5]和抑制剂2)。其中一些多肽表达升高通过免疫印迹和免疫组织化学得到证实,而其他一些的表达升高未能得到证实,这说明了确证性研究的重要性。本研究描述了一种鉴定MCL中失调蛋白的新技术。